2024
Systemic Therapy for Advanced Hepatocellular Carcinoma: ASCO Guideline Update
Gordan J, Kennedy E, Abou-Alfa G, Beal E, Finn R, Gade T, Goff L, Gupta S, Guy J, Hoang H, Iyer R, Jaiyesimi I, Jhawer M, Karippot A, Kaseb A, Kelley R, Kortmansky J, Leaf A, Remak W, Sohal D, Taddei T, Wilson Woods A, Yarchoan M, Rose M. Systemic Therapy for Advanced Hepatocellular Carcinoma: ASCO Guideline Update. Journal Of Clinical Oncology 2024, 42: 1830-1850. PMID: 38502889, DOI: 10.1200/jco.23.02745.Peer-Reviewed Original ResearchTyrosine kinase inhibitorsAdvanced hepatocellular carcinomaSecond-line therapyFirst-line treatmentRandomized controlled trialsHepatocellular carcinomaSystemic therapyFirst-lineChild-Pugh class A liver diseaseEastern Cooperative Oncology Group performance status 0Child-Pugh class A patientsSecond-line therapy optionsFirst-line settingPerformance status 0Third-line therapyFirst-line therapyClass A patientsEvidence-based guidelinesTolerated sorafenibStatus 0A patientsMechanism of actionTherapy optionsClinical decision-makingGuideline update
2020
Systemic Therapy for Advanced Hepatocellular Carcinoma: ASCO Guideline.
Gordan JD, Kennedy EB, Abou-Alfa GK, Beg MS, Brower ST, Gade TP, Goff L, Gupta S, Guy J, Harris WP, Iyer R, Jaiyesimi I, Jhawer M, Karippot A, Kaseb AO, Kelley RK, Knox JJ, Kortmansky J, Leaf A, Remak WM, Shroff RT, Sohal DPS, Taddei TH, Venepalli NK, Wilson A, Zhu AX, Rose MG. Systemic Therapy for Advanced Hepatocellular Carcinoma: ASCO Guideline. Journal Of Clinical Oncology 2020, 38: 4317-4345. PMID: 33197225, DOI: 10.1200/jco.20.02672.Peer-Reviewed Original ResearchConceptsAdvanced hepatocellular carcinomaFirst-line treatmentSecond-line therapyChild-Pugh classFirst-line therapyHepatocellular carcinomaSystemic therapyLiver diseaseTherapy optionsEastern Cooperative Oncology Group performance status 0Evidence-based clinical practice guidelinesSecond-line therapy optionsTyrosine kinase inhibitor sorafenibECOG PS 0Performance status 0Third-line therapyPhase IIIClinical practice guidelinesKinase inhibitor sorafenibTyrosine kinase inhibitorsAppropriate candidatesStatus 0ASCO guidelinesMost patientsPS 0